Polyanalgesic consensus conference-2012: Recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain

Timothy R. Deer, Robert Levy, Joshua Prager, Eric Buchser, Allen Burton, David Caraway, Michael Cousins, José De Andrés, Sudhir Diwan, Michael Erdek, Eric Grigsby, Marc Huntoon, Marilyn S. Jacobs, Philip Kim, Krishna Kumar, Michael Leong, Liong Liem, Gladstone C. McDowell, Sunil Panchal, Richard RauckMichael Saulino, B. Todd Sitzman, Peter Staats, Michael Stanton-Hicks, Lisa Stearns, Mark Wallace, K. Dean Willis, William Witt, Tony Yaksh, Nagy Mekhail

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Targeted intrathecal drug infusion to treat moderate to severe chronic pain has become a standard part of treatment algorithms when more conservative options fail. This therapy is well established in the literature, has shown efficacy, and is an important tool for the treatment of both cancer and noncancer pain; however, it has become clear in recent years that intrathecal drug delivery is associated with risks for serious morbidity and mortality. Methods: The Polyanalgesic Consensus Conference is a meeting of experienced implanting physicians who strive to improve care in those receiving implantable devices. Employing data generated through an extensive literature search combined with clinical experience, this work group formulated recommendations regarding awareness, education, and mitigation of the morbidity and mortality associated with intrathecal therapy to establish best practices for targeted intrathecal drug delivery systems. Results: Best practices for improved patient care and outcomes with targeted intrathecal infusion are recommended to minimize the risk of morbidity and mortality. Areas of focus include respiratory depression, infection, granuloma, device-related complications, endocrinopathies, and human error. Specific guidance is given with each of these issues and the general use of the therapy. Conclusions: Targeted intrathecal drug delivery systems are associated with risks for morbidity and mortality that can be devastating. The panel has given guidance to treating physicians and healthcare providers to reduce the incidence of these problems and to improve outcomes when problems occur.

Original languageEnglish (US)
Pages (from-to)467-482
Number of pages16
JournalNeuromodulation
Volume15
Issue number5
DOIs
StatePublished - Sep 2012

Keywords

  • Chronic pain
  • consensus
  • intrathecal
  • morbidity
  • mortality
  • opioids
  • outcomes

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint

Dive into the research topics of 'Polyanalgesic consensus conference-2012: Recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain'. Together they form a unique fingerprint.

Cite this